Patents by Inventor Charles S. Yeung

Charles S. Yeung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ARYL ETHER COMPOUNDS AS TEAD MODULATORS
    Publication number: 20240083903
    Abstract: The present invention is directed to a compound of Formula I: or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions comprising them and methods of using such compounds or pharmaceutical salts thereof.
    Type: Application
    Filed: February 15, 2022
    Publication date: March 14, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Jongwon Lim, Vladimir Simov, Brandon A. Vara, Charles S. Yeung, Sebastian E. Schneider, Erin F. DiMauro
  • PRMT5 INHIBITORS
    Publication number: 20230114091
    Abstract: The present invention provides a compound of Formula (I) (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.
    Type: Application
    Filed: December 14, 2020
    Publication date: April 13, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Michelle Machacek, Michael D. Altman, Shuhei Kawamura, Michael H. Reutershan, David L. Sloman, Phieng Siliphaivanh, Sebastian E. Schneider, Charles S. Yeung, David J. Witter, Craig R. Gibeau
  • PRMT5 INHIBITORS
    Publication number: 20230108114
    Abstract: The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.
    Type: Application
    Filed: December 14, 2020
    Publication date: April 6, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Michelle Machacek, Michael D. Altman, Chunghui Huang, Michael H. Reutershan, David L. Sloman, Phieng Siliphaivanh, Sebastian E. Schneider, Charles S. Yeung, David J. Witter, Craig R. Gibeau, Yingchun Ye
  • PRMT5 INHIBITORS
    Publication number: 20220363707
    Abstract: The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.
    Type: Application
    Filed: August 5, 2019
    Publication date: November 17, 2022
    Applicants: Merck Sharp & Dohme Corp., MSD International GmbH
    Inventors: Michelle Machacek, David Witter, Craig Gibeau, Chunhui Huang, Shuhei Kawamura, David L. Sloman, Phieng Siliphaivanh, Ryan Quiroz, Murray Wan, Sebastian Schneider, Charles S. Yeung, Michael H. Reutershan, Timothy J. Henderson, Jean-Laurent Paparin, Houcine Rahali, Jonathan M. E. Hughes, Sulagna Sanyal, Yingchun Ye, David A. Candito, Patrick S. Fier, Steven M. Silverman
  • PRMT5 INHIBITORS
    Publication number: 20210277009
    Abstract: The present invention provides a compound of Formula (I) Formula (I) or the pharmaceutically acceptable salts thereof, which are PRMT5 inhibitors.
    Type: Application
    Filed: August 5, 2019
    Publication date: September 9, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: David Witter, Shuhei Kawamura, Michelle Machacek, Ryan Quiroz, Michael H. Reutershan, Sebastian Schneider, Phieng Siliphaivanh, Yingchun Ye, Charles S. Yeung